Table 1. Effects of bevacizumab on thoracic tumours in mice.
| Y-MESO-14 |
Thoracic tumour |
Pleural effusion |
||
|---|---|---|---|---|
| Incidence | Weight (mg) | Incidence | Volume (μl) | |
| Control (n=4) | 4/4 | 260 (210–330) | 4/4 | 290 (200–700) |
| Bev 10 μg (n=5) | 5/5 | 170 (100–250)* | 4/5 | 50 (0–250)* |
| PC14PE6 |
Lung |
Pleural effusion |
|||
|---|---|---|---|---|---|
| Weight (mg) |
Metastasis |
Incidence | Volume (μl) | ||
| Incidence | Number | ||||
| Control (n=7) | 480 (320–880) | 7/7 | 62 (25–87) | 6/7 | 520 (0–750) |
| Bev 10 μg (n=7) | 180 (170–200)† | 6/7 | 17 (0–42)† | 0/7 | 0 |
| Bev 30 μg (n=7) | 180 (150–250)† | 7/7 | 29 (4–101)* | 0/7 | 0 |
MPM, malignant pleural mesothelioma; SCID, severe combined immunodeficient
Y-MESO-14 (human MPM) cells were orthotopically injected to SCID mice, and PC14PE6 (human lung adenocarcinoma) cells were intravenously injected to nude mice. These mice were treated with bevacizumab (Bev) from day 7 after the tumour cell injection, and thoracic tumour, lung metastasis and pleural effusion were evaluated on day 28 (Y-MESO-14) or on day 35 (PC14PE6) after tumour cell injection. Values are the median (minimum–maximum).
*Statistically significant difference compared with control group (P<0.05) by the Mann–Whitney-U-test.
†Statistically significant difference compared with control group (P<0.01) by the Mann–Whitney-U-test.